Magnetar Financial LLC Acquires 38,648 Shares of Prestige Consumer Healthcare Inc. $PBH

Magnetar Financial LLC lifted its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 231.9% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 55,316 shares of the company’s stock after buying an additional 38,648 shares during the period. Magnetar Financial LLC owned about 0.11% of Prestige Consumer Healthcare worth $4,417,000 as of its most recent filing with the SEC.

Several other large investors have also bought and sold shares of PBH. Kayne Anderson Rudnick Investment Management LLC raised its stake in Prestige Consumer Healthcare by 45.3% during the first quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,580,819 shares of the company’s stock worth $135,903,000 after acquiring an additional 493,199 shares in the last quarter. Geode Capital Management LLC lifted its stake in Prestige Consumer Healthcare by 0.7% in the 2nd quarter. Geode Capital Management LLC now owns 1,413,041 shares of the company’s stock valued at $112,843,000 after purchasing an additional 9,455 shares during the last quarter. Invesco Ltd. boosted its position in Prestige Consumer Healthcare by 24.7% in the first quarter. Invesco Ltd. now owns 1,321,800 shares of the company’s stock valued at $113,635,000 after buying an additional 261,537 shares in the last quarter. Congress Asset Management Co. grew its stake in shares of Prestige Consumer Healthcare by 1.8% during the second quarter. Congress Asset Management Co. now owns 1,009,595 shares of the company’s stock worth $80,616,000 after buying an additional 18,015 shares during the last quarter. Finally, Westwood Holdings Group Inc. increased its holdings in shares of Prestige Consumer Healthcare by 2.4% during the second quarter. Westwood Holdings Group Inc. now owns 881,908 shares of the company’s stock worth $70,420,000 after buying an additional 20,626 shares in the last quarter. 99.95% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

PBH has been the topic of several recent research reports. Canaccord Genuity Group cut their price objective on Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating on the stock in a report on Friday, November 7th. Wall Street Zen lowered Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research note on Saturday, August 9th. Zacks Research raised Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research note on Monday, November 10th. Jefferies Financial Group dropped their price objective on shares of Prestige Consumer Healthcare from $75.00 to $71.00 and set a “hold” rating for the company in a report on Monday, October 27th. Finally, Sidoti raised shares of Prestige Consumer Healthcare from a “neutral” rating to a “buy” rating and set a $80.00 target price on the stock in a report on Wednesday, September 24th. Four equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $85.33.

Prestige Consumer Healthcare Stock Performance

Shares of PBH opened at $59.43 on Friday. The company has a current ratio of 4.38, a quick ratio of 2.99 and a debt-to-equity ratio of 0.55. The firm’s fifty day simple moving average is $61.74 and its two-hundred day simple moving average is $71.73. Prestige Consumer Healthcare Inc. has a 12 month low of $58.03 and a 12 month high of $90.04. The stock has a market capitalization of $2.86 billion, a P/E ratio of 13.95, a price-to-earnings-growth ratio of 1.93 and a beta of 0.41.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings data on Thursday, November 6th. The company reported $1.07 earnings per share for the quarter, topping the consensus estimate of $0.97 by $0.10. Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%.The firm had revenue of $274.11 million during the quarter, compared to analyst estimates of $257.14 million. During the same period last year, the company posted $1.09 EPS. The business’s quarterly revenue was down 3.4% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. As a group, analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.